DK1123414T3 - Antisense-modulering af integrin alpha 4.ekspression - Google Patents

Antisense-modulering af integrin alpha 4.ekspression

Info

Publication number
DK1123414T3
DK1123414T3 DK99942290T DK99942290T DK1123414T3 DK 1123414 T3 DK1123414 T3 DK 1123414T3 DK 99942290 T DK99942290 T DK 99942290T DK 99942290 T DK99942290 T DK 99942290T DK 1123414 T3 DK1123414 T3 DK 1123414T3
Authority
DK
Denmark
Prior art keywords
expression
integrin alpha
antisense modulation
modulating
methods
Prior art date
Application number
DK99942290T
Other languages
English (en)
Inventor
C Frank Bennett
Thomas P Condon
Lex M Cowsert
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1123414T3 publication Critical patent/DK1123414T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
DK99942290T 1998-10-05 1999-08-19 Antisense-modulering af integrin alpha 4.ekspression DK1123414T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/166,203 US5968826A (en) 1998-10-05 1998-10-05 Antisense inhibition of integrin α4 expression
PCT/US1999/018796 WO2000020635A1 (en) 1998-10-05 1999-08-19 ANTISENSE MODULATION OF INTEGRIN α4 EXPRESSION

Publications (1)

Publication Number Publication Date
DK1123414T3 true DK1123414T3 (da) 2007-04-10

Family

ID=22602243

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99942290T DK1123414T3 (da) 1998-10-05 1999-08-19 Antisense-modulering af integrin alpha 4.ekspression

Country Status (10)

Country Link
US (2) US5968826A (da)
EP (1) EP1123414B1 (da)
JP (2) JP3834204B2 (da)
AT (1) ATE352639T1 (da)
AU (1) AU759938B2 (da)
CA (1) CA2345209C (da)
DE (1) DE69934998T2 (da)
DK (1) DK1123414T3 (da)
ES (1) ES2279632T3 (da)
WO (1) WO2000020635A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515513A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド 核酸の肺送達のための組成物および方法
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
DE19860642A1 (de) * 1998-12-29 2000-07-06 Deutsches Krebsforsch Antisense-Oligonukleotid zur Hemmung der Expression des Adhäsionsmoleküls very late antigen 4 (VLA-4) in menschlichen Zellen
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
AU2003288898A1 (en) * 2002-08-19 2004-03-29 Pharmacia Corporation Antisense modulation of endothelial specific molecule 1 expression
CA2545248A1 (en) * 2003-09-29 2005-04-14 The Regents Of The University Of California Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
CA2584614A1 (en) 2004-10-20 2006-08-24 Antisense Therapeutics Ltd Antisense modulation of integrin .alpha.4 expression
US7879816B2 (en) * 2005-06-07 2011-02-01 Yale University Methods of treating cancer and other conditions or disease states using LFMAU and LDT
EP2656850B1 (en) * 2007-10-05 2016-07-27 InDex Pharmaceuticals AB Oligonucleotides for the treatment or alleviation of edema
ES2699891T3 (es) * 2008-06-23 2019-02-13 Antisense Therapeutics Ltd Métodos para tratar la esclerosis múltiple usando oligonucleótidos antisentido
EP2616081A4 (en) * 2010-09-17 2014-01-01 Antisense Therapeutics Ltd METHOD FOR MOBILIZING STEM AND / OR PROGENITOR CELLS
WO2014193625A1 (en) * 2013-05-30 2014-12-04 R-Pharm Overseas, Inc. Fully human antibodies against human receptor integrin alpha-4
AU2016259971B2 (en) * 2015-05-11 2021-12-09 ProGenis Pty Ltd Multiple sclerosis treatment
ES2938883T3 (es) * 2015-11-05 2023-04-17 Los Angeles Childrens Hospital Oligo antisentido para su uso en el tratamiento de la leucemia mieloide aguda
JPWO2018174140A1 (ja) * 2017-03-23 2020-04-09 ナパジェン ファーマ, インコーポレテッドNapaJen Pharma, Inc. 癌細胞の接着活性阻害剤
WO2023039643A1 (en) * 2021-09-20 2023-03-23 Antisense Therapeutics Ltd Methods and kits therefor
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
CN114887034B (zh) * 2022-07-14 2022-10-28 中山莱博瑞辰生物医药有限公司 LLP2A-Ale在制备用于治疗和/或预防外周血淋巴细胞减少症的药物中的用途
WO2024036373A1 (en) * 2022-08-16 2024-02-22 Antisense Therapeutics Ltd Biomarkers and uses thereof in diagnosis and treatment of neurological post acute sequelae of covid 19 (npasc)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression

Also Published As

Publication number Publication date
WO2000020635A1 (en) 2000-04-13
JP3834204B2 (ja) 2006-10-18
ES2279632T3 (es) 2007-08-16
CA2345209C (en) 2014-04-22
US5968826A (en) 1999-10-19
JP2002526555A (ja) 2002-08-20
JP2006141402A (ja) 2006-06-08
EP1123414A1 (en) 2001-08-16
ATE352639T1 (de) 2007-02-15
JP4168285B2 (ja) 2008-10-22
AU759938B2 (en) 2003-05-01
AU5570399A (en) 2000-04-26
EP1123414B1 (en) 2007-01-24
US6258790B1 (en) 2001-07-10
DE69934998D1 (de) 2007-03-15
CA2345209A1 (en) 2000-04-13
DE69934998T2 (de) 2007-12-06
EP1123414A4 (en) 2003-10-01

Similar Documents

Publication Publication Date Title
DK1117672T3 (da) Antisense-modulation af survivin-ekpression
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
DE60143901D1 (de) Antisense-modulation der clusterinexpression
DK1250455T3 (da) Antisense-inhibering af PTP1B-ekspression
WO2002036743A3 (en) Antisense modulation of calreticulin expression
EP1131465A4 (en) ANTISENSE MODULATION OF THE INTERLEUKIN-15 EXPRESSION
EP1248791A4 (en) ANTI-SENSE MODULATION OF CASPASE 3 EXPRESSION
EP1189918A4 (en) ANTISENSE MODULATION OF INTEGRIN BETA 3 EXPRESSION
EP1135402A4 (en) ANTISENSE MODULATION OF THE EGR-1 EXPRESSION
EP1131107A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INHIBITOR-KAPPA-B-KINASE-ALPHA
EP1131332A4 (en) ANTISENSE MODULATION OF KAPPA B KINASE BETA INHIBITOR EXPRESSION
WO2001029175A3 (en) Antisense modulation of fra-1 expression
EP1212456A4 (en) ANTISENSE MODULATION OF SHP-2 EXPRESSION
WO2003008545A3 (en) Antisense modulation of glioma-associated oncogene-2 expression
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
EP1144690A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF A CELLULAR APOPTOSIS-2 INHIBITOR
EP1218395A4 (en) ANTISENSE MODULATION OF X-CONNECTED INHIBITORS OF APOPTOSIS EXPRESSION
WO2000061786A3 (en) Antisense modulation of pdk-1 expression
WO2003033659A3 (en) Antisense modulation of matrix metalloproteinase 1 expression
EP1210454A4 (en) ANTISENSE MODULATION OF SHP-1 EXPRESSION
WO2002055535A3 (en) Antisense modulation of cytohesin-1 expression
WO2003106645A3 (en) ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION
WO2003050247A3 (en) Antisense modulation of mhc class ii transactivator expression
WO2002024864A3 (en) Antisense modulation of syntaxin 4 interacting protein expression
WO2003008549A3 (en) Antisense modulation of glioma-associated oncogene-3 expression